Arbutus Biopharma Logo
Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
December 01, 2021 11:58 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
VIR_logo_large.jpg
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®
November 12, 2021 08:00 ET | Vir Biotechnology, Inc.
– New data from ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate notable reductions in HBsAg and support their positive safety profiles – SAN FRANCISCO, Nov. 12, 2021 ...
VIR_logo_large.jpg
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET | Vir Biotechnology, Inc.
– To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide – – In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration...
Arbutus Biopharma Logo
Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021
November 01, 2021 16:05 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
VIR_logo_large.jpg
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021
October 21, 2021 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter...
VIR_logo_large.jpg
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
October 15, 2021 08:30 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B clinical program and one health...
Black-Enochian-Primary-Logo.jpg
Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
October 12, 2021 18:00 ET | Enochian BioSciences, Inc.
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
VIR_logo_large.jpg
Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
October 06, 2021 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the H. C....
VIR_logo_large.jpg
Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference
September 30, 2021 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the Guggenheim...
Black-Enochian-Primary-Logo.jpg
Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection
September 27, 2021 07:00 ET | Enochian BioSciences, Inc.
LOS ANGELES, Sept. 27, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...